NORTHERA® (droxidopa) stands by you and your patients every step of the way with a variety of resources to support your practice and to help your patients throughout their treatment journey.
Get patients started on NORTHERA by completing and faxing this form to the Northera Support Center (NSC).
Your comprehensive resource for information on NORTHERA, including appropriate patients, efficacy data, safety information, titration and dosing guidance, real-world experience, and access.
Refer to this brochure for comprehensive titration and dosing information for NORTHERA.
Review this guide with patients to help them understand the importance of titration when determining individual doses for symptomatic relief.
Read about a real patient’s journey with symptomatic nOH and her experience managing it with NORTHERA.
Share this diary with patients to help them monitor their symptoms and blood pressure readings throughout treatment.
Learn about eligibility requirements and how to get patients enrolled in the program to help them save on treatment.
Indications and Usage
NORTHERA (droxidopa) is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson’s disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically.
Important Safety Information
WARNING: SUPINE HYPERTENSION
Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA.
WARNINGS AND PRECAUTIONS
USE IN SPECIFIC POPULATIONS
For more information, please see the full Prescribing Information, including Boxed Warning for supine hypertension.